Comment from MitoAction

Summary: MitoAction, a national patient advocacy organization, supports the FDA's Patient-Focused Drug Development (PFDD) meetings and highlights their success in establishing a shared understanding of mitochondrial disease burden. They argue that these meetings should serve as the start of an ongoing partnership with the FDA to ensure patient experience data evolves alongside scientific discoveries.